Genincode PLC
LSE:GENI
Net Margin
Genincode PLC
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
UK |
G
|
Genincode PLC
LSE:GENI
|
5.2m GBP |
-164%
|
|
US |
![]() |
Cigna Corp
NYSE:CI
|
75.8B USD |
2%
|
|
US |
![]() |
CVS Health Corp
NYSE:CVS
|
81.9B USD |
1%
|
|
US |
C
|
Cigna Group
XMUN:CGN
|
67.7B EUR |
2%
|
|
DE |
![]() |
Fresenius Medical Care AG
XMUN:FME
|
26.4B EUR |
3%
|
|
DE |
![]() |
Fresenius SE & Co KGaA
XETRA:FRE
|
23.7B EUR |
2%
|
|
US |
![]() |
Laboratory Corporation of America Holdings
NYSE:LH
|
21.8B USD |
6%
|
|
US |
![]() |
Quest Diagnostics Inc
NYSE:DGX
|
19B USD |
9%
|
|
DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
13B EUR |
3%
|
|
US |
![]() |
Hims & Hers Health Inc
NYSE:HIMS
|
15.4B USD |
9%
|
|
US |
![]() |
DaVita Inc
NYSE:DVA
|
11.1B USD |
7%
|
Genincode PLC
Glance View
GENinCode UK Ltd. engages in the risk assessment and prediction of cardiovascular disease. The company is headquartered in Oxford, Oxfordshire. The company went IPO on 2021-07-22. The firm develops patented deoxyribonucleic acid (DNA) risk assessment products which utilize artificial intelligence (AI), bioinformatics and a globally recognized clinical evidence base to provide predictive analysis of a patient’s health risk. The Company’s clinical diagnostic tests cover global disease areas such as cardiovascular, cancer and diabetes.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Genincode PLC's most recent financial statements, the company has Net Margin of -164.2%.